Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Departure of Directors or Certain Officers
18 Apr 24
S-3ASR
Automatic shelf registration
1 Mar 24
8-K
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
29 Feb 24
8-K
Sana Biotechnology Announces Pricing of Upsized Public Offering
8 Feb 24
424B5
Prospectus supplement for primary offering
8 Feb 24
FWP
Free writing prospectus
7 Feb 24
424B5
Prospectus supplement for primary offering
7 Feb 24
8-K
Results of Operations and Financial Condition
7 Feb 24
8-K
Regulation FD Disclosure
9 Jan 24
8-K
Regulation FD Disclosure
11 Dec 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates
8 Nov 23
8-K
Cost Associated with Exit or Disposal Activities
10 Oct 23
8-K
Regulation FD Disclosure
13 Sep 23
8-K
Termination of a Material Definitive Agreement
21 Aug 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates
3 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 23
8-K
Regulation FD Disclosure
7 Jun 23
S-8
Registration of securities for employees
8 May 23
10-Q
2023 Q1
Quarterly report
8 May 23
8-K
Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates
8 May 23
EFFECT
Notice of effectiveness
2 May 23
POS EX
Additional exhibits for listing
1 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
8-K
Departure of Directors or Certain Officers
28 Apr 23
8-K
Sana Biotechnology Announces the Appointment of Two Pioneers in Drug Discovery and Development to Lead its R&D Organization
10 Apr 23
POS AM
Prospectus update (post-effective amendment)
16 Mar 23
10-K
2022 FY
Annual report
16 Mar 23
8-K
Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
16 Mar 23
POSASR
Automatic shelf registration (post-effective amendment)
15 Mar 23
8-K
Goal is to report initial SC291 clinical data this year
26 Jan 23
8-K
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies
26 Jan 23
8-K
Regulation FD Disclosure
10 Jan 23
8-K
Sana Biotechnology Confirms Key Program Timelines and Announces Portfolio Prioritization
29 Nov 22
Latest ownership filings
4
Hans Edgar Bishop
8 Apr 24
3
Initial statement of insider ownership
8 Apr 24
SC 13G/A
FMR LLC
3 Apr 24
4
Patrick Y Yang
11 Mar 24
4
DOUGLAS E WILLIAMS
8 Mar 24
4
Steve Harr
8 Mar 24
4
Christian Hordo
8 Mar 24
4
Nathan Hardy
8 Mar 24
4
Bernard J Cassidy
8 Mar 24
SC 13G/A
BAILLIE GIFFORD & CO
7 Mar 24
SC 13G/A
Flagship Ventures Fund V, L.P.
14 Feb 24
4
NOUBAR AFEYAN
14 Feb 24
3
Initial statement of insider ownership
14 Feb 24
4
ROBERT NELSEN
12 Feb 24
4
KEITH CRANDELL
12 Feb 24
4
Change in insider ownership
12 Feb 24
SC 13G/A
ARCH Venture Fund IX, L.P.
9 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G/A
BAILLIE GIFFORD & CO
26 Jan 24
4
Hans Edgar Bishop
8 Jan 24
4
Mary Agnes Wilderotter
8 Jan 24
4
Christian Hordo
18 Dec 23
144
Notice of proposed sale of securities
15 Dec 23
4
DOUGLAS E WILLIAMS
3 Nov 23
4
Christian Hordo
3 Nov 23
4
Nathan Hardy
3 Nov 23
4
Mary Agnes Wilderotter
6 Oct 23
4
Hans Edgar Bishop
6 Oct 23
4
NOUBAR AFEYAN
15 Sep 23
4
Mary Agnes Wilderotter
6 Jul 23
4
Hans Edgar Bishop
6 Jul 23
4
ROBERT NELSEN
12 Jun 23
4
ALISE REICIN
9 Jun 23
4
Joshua H. Bilenker
9 Jun 23
4
Michelle Seitz
9 Jun 23
4
Mary Agnes Wilderotter
9 Jun 23
4
Douglas G. Cole
9 Jun 23
4
Patrick Y Yang
9 Jun 23
4
Hans Edgar Bishop
9 Jun 23
4
NOUBAR AFEYAN
8 Jun 23